UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2024 P 1275-7
Program Prior Authorization/Notification
Medication Firdapse® (amifampridine)
P&T Approval Date 2/2019, 1/2020, 1/2021, 1/2022, 11/2022, 11/2023. 11/2024
Effective Date 2/1/2025
1. Background:
Firdapse (amifampridine) is a potassium channel blocker indicated for the treatment of Lambert-
Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.
2. Coverage Criteriaa:
A. Initial Authorization
1. Firdapse will be approved based on both of the following criteria:
a. Diagnosis of Lambert-Eaton myasthenic syndrome (LEMS)
-AND-
b. Patient is not receiving Firdapse in combination with similar potassium channel
blockers [e.g., Ampyra (dalfampridine)]
Authorization will be issued for 12 months.
B. Reauthorization
1. Firdapse will be approved based on both the following criteria:
a. Documentation of positive clinical response to Firdapse therapy
-AND-
b. Patient is not receiving Firdapse in combination with similar potassium channel
blockers [e.g., Ampyra (dalfampridine)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
© 2024 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Programs:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits and Medical Necessity may be in place.
4. References:
1. Firdapse [package insert]. Catalyst Pharmaceuticals, Inc. Coral Gables, FL. May 2024.
Program Prior Authorization/Notification - Firdapse (amifampridine)
Change Control
2/2019 New program
1/2020 Annual review with no changes.
1/2021 Annual review with no changes.
1/2022 Annual review with no change to clinical criteria. Updated reference.
11/2022 Updated background to reflect new pediatric indication for patients 6
years of age and older. Added state mandate footnote.
11/2023 Added “Diagnosis of” to initial criteria with no change to clinical intent.
11/2024 Annual review with no changes to coverage criteria. Updated reference.
© 2024 UnitedHealthcare Services, Inc.
2